Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

faldaprevir

- PMLiVE

Novartis signs stem cell research pact with Intellia

Will work with the biotech start-up on creating new treatments

Novartis day

FDA close to first biosimilar approval

US regulator’s advisory board recommends Novartis’ version of Amgen’s Neupogen

- PMLiVE

Japan first to approve Novartis psoriasis drug Cosentyx

Becomes first company to gain approval for an interleukin-17 inhibitor

- PMLiVE

EMA picks projects for adaptive licensing project

Begins discussions on how the model will be implemented in practice

- PMLiVE

Orexigen’s obesity pill Mysimba set for European approval

But sales of the treatment are only predicted to reach $200m by 2016

- PMLiVE

‘Major step forward’ as EMA recommends first stem cell therapy

But wants more clinical trial data to shore up orphan drug's marketing licence

- PMLiVE

Data transparency in Europe

Will 2015 usher in a new era?

- PMLiVE

Novartis’ acromegaly therapy cleared by FDA

Signifor LAR shows superior efficiency to older treatments

- PMLiVE

NICE recommends Pradaxa in blood clot indication

Boehringer drug backed to treat and prevent deep vein thrombosis and pulmonary embolism

- PMLiVE

EMA: Lack of evidence for Ebola treatments

Not enough data to draw conclusions on effectiveness of experimental drugs

- PMLiVE

Novartis’ Afinitor fails frontline breast cancer trial

Drug already approved to treat HER2-negative breast cancer

EU flag

EC: Search for Rasi’s replacement could take six months

Commission tells PMLiVE process could still be impacted by the procedure's complexity

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links